The objectives of the present study were to demonstrate the antihyperuricemic effect of triphala, a formulation of traditional Ayurvedic medicine, in potassium oxonate-induced hyperuricemic mice in vivo, and to examine its inhibitory effects on xanthine oxidase (XOD), inflammatory mediators and DPPH radicals in vitro. The water extract of triphala was determined to contain the total phenolics and total flavonoids of 317.6 ± 9.2 mg GAE/g and 7.73 ± 0.26 mg QE/g, respectively. Oral administrations of triphala significantly reduced the plasma uric acid levels of potassium oxonate-induced hyperuricemic mice at doses of 1,000 and 1,500 mg/kg, as compared with control (p<0.05). Moreover, both doses of triphala treatments markedly inhibited the formation of uric acid due to inhibition of XOD activity in liver homogenates extracted from the hyperuricemic mice by about 70-80%. Lineweaver-Burk analysis of enzyme-kinetic data showed that triphala exhibited non-competitive inhibition on XOD activity in vitro with an inhibitory constant (K i ) of 590 g/mL. Furthermore, triphala significantly suppressed the mRNA expressions of COX-II, TNF- and iNOS in LPS-stimulated RAW 264.7 cells, as compared with control (p<0.05), and decreased the expression of TGF-. IC 50 values for inhibition of DPPH radical formation was calculated to be 21.9 ± 2.50 μg/mL. Antioxidant activities of triphala were determined to be 0.81 ± 0.07 g TEAC/g and 6.78 ± 0.29 mmol/100g, respectively, as assessed by ABTS and FRAP assays. In conclusion, this study provided in vivo and in vitro mechanistic evidence for the antihyperuricemic, antioxidative and anti-inflammatory effects of triphala for the first time, rationalizing its therapeutic usage for the treatment of hyperuricemia of gout.
Triphala is the well-known formulation of a traditional Ayurvedic medicine, which is a mixture of three fruits, Phyllanthus emblica Linn., Terminalia belerica Linn. and T. chebula Retz. in equal proportions. Triphala contains a number of phytochemical compounds such as ellagic acid, gallic acid, chebulinic acid, bellericanin, β-sitosterol and flavonoids in high amounts, in consistent with its antioxidative effects via scavenging of hydroxyl radicals and superoxide radicals. Various pharmacological effects of triphala have been reported [1] , including alleviation of inflammatory processes in gouty arthritis rats and mice models [2] [3] [4] . To our knowledge, there is only one in vitro study that reported the inhibitory effect of triphala on xanthine oxidase (XOD) [5] , but its direct effect on XOD has not been evaluated under in vivo or in vitro conditions so far. Therefore, the present study was conducted to demonstrate the antihyperuricemic effect of triphala in potassium oxonate-induced hyperuricemic mice in vivo, and to examine its inhibitory effects on XOD activity, mRNA expression of inflammatory mediators and DPPH radical formation in vitro.
Since gallic and ellagic acids contained in triphala are known to have inhibitory effects on XOD activity [1] , these acids were employed as standard markers for the quality control of triphala ( Figure 1 ). The amounts of ellagic and gallic acids in the triphala extract were quantitated by HPLC to be 19.25 ± 0.06 and 97.28 ± 2.52 mg/g extract, respectively. The obtained freeze-dried powder of triphala was in brownish color and its yielding extract was determined to be 24.82%. In vivo effects of triphala on uric acid concentration in plasma are presented in Figure 2 . Uric acid level in plasma of the untreated hyperuricemic group was elevated significantly after an i.p. injection of potassium oxonate, compared with the normal control group (43.1 ± 13.4 vs. 8.7 ± 2.2 µg/mL, p < 0.01). Plasma uric acid concentration was significantly reduced by about 88% after pretreatment with allopurinol, as compared with the untreated hyperuricemic group (p<0.01). Uric acid concentration was decreased by about 17% after oral treatment with 500 mg/kg triphala, but not with a significant difference. Treatments with triphala at doses of 1,000 and 1,500 mg/kg significantly decreased plasma uric acid concentrations by 36% and 50% (p<0.05), respectively, as compared with the untreated hyperuricemic control group. The effective triphala dose (1,000 mg/kg) is corresponding to that reported for the anti-inflammatory effect of triphala [3, 4] , where triphala significantly inhibited the inflammatory mediators in the monosodium urate (MSU) crystal-induced arthritis mice. Altogether, these observations support the therapeutic use of triphala for the treatment of hyperuricemia and inflammatory in gout.
Moreover, we found that ex vivo formation of uric acid (i.e., XOD activity) in the liver homogenates extracted from mice treated with triphala at doses of 500, 1,000 and 1,500 mg/kg were significantly decreased by 44.4%, 78.6% and 80.4%, respectively, as compared with the untreated hyperuricemic group (p<0.01) ( Table 1 ).
In consistent with a previous report [5] , our in vitro data indicated that triphala inhibited the XOD activity in a concentrationdependent manner, and its IC 50 was determined to be 220.4 ± 4.5 g/mL, while that of the positive control, allopurinol, was 3.78 ± 0.08 μg/mL. Unlike allopurinol which is a competitive inhibitor of xanthine oxidase [6] , the Lineweaver-Burk analysis of the enzymekinetic data showed that the presence of triphala ( Figure 3 ) caused a decrease in V max of XOD activity compared to the control, without changing in K m of xanthine, indicating a non -competitive inhibition type in which active components in triphala are considered to bind to another site of the substrate binding site and subsequently inhibit the enzyme activity. The K i value of triphala was determined to be 590 g/mL.
The present study provided direct in vivo evidence for the antihyperuricemic effect of triphala by using potassium oxonateinduced hyperuricemic mice. Moreover, results obtained from the ex vivo experiments showed that triphala significantly decreased the formation of uric acid due to inhibition of XOD activity in the liver homogenates, indicating that active components of triphala can be absorbed orally, distributed into the liver tissue and consequently served to inhibit the XOD activity. Figure 4 presents the viability of RAW264.7 cells in the presence of triphala as compared with the control (without triphala). It was found that triphala did not show any cytotoxicity over the concentration range 0.01-10 μg/mL; therefore, the triphala concentrations of 0.01-10 µg/mL were employed for the subsequent in vitro experiments.
For the determination of anti-inflammatory effect of triphala, the inhibition of mRNA expression of lipopolysaccharide (LPS)induced inflammatory mediators were examined using RAW264.7 macrophage cells. As shown in Figure 5 , LPS (1 µg/mL) strongly up-regulated cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), transforming growth factor-β (TGF-β) and tumor necrosis factor-α (TNF-α) mRNA expressions of the RAW 264.7 cells compared to the control. LPS-induced mRNA expressions of COX-II, iNOS and TNF-α were attenuated significantly by pretreatment of the cells with triphala (10 µg/mL), as shown in Figures 5a, 5b and 5d, respectively, as compared with the control (LPS only, p<0.05), and LPS-induced mRNA expression of TGF- tended to decrease by pretreatment with triphala ( Figure 5c ). The anti-inflammatory activity of triphala observed in this study is consistent with the study performed in gouty arthritis mice and rat models [3] [4] . The presence of phytochemicals such as flavonoids and phenolics in the triphala extract may be responsible for the antiinflammatory effect.
After extracted by water, total contents of phenolics and flavonoids in triphala were determined to be 317.6 ± 9.2 mg GAE/g and 7.73 ± 0.26 mg QE/g, respectively. In accordance with previously reported studies [1, 5] , triphala exhibited a strong antioxidant activity. The IC 50 values for the inhibition of DPPH radicals by triphala was calculated to be 21.97 ± 2.50 μg/mL. Antioxidant activities measured by ABTS and FRAP assays were determined to be 0.81 ± 0.07 g TEAC/g and 6.78 ± 0.29 mmol/100g, respectively. The extracts of P. emblica, T. chebula and T. belerica have been considered to be safe, since no toxicity of triplala was found in rats when these herbs were orally administered for ten days at doses up to 23.04 g/kg/day [7] . Therefore, the water extract of triphala was considered to be a good candidate of natural remedy supplementation for antihyperuricemia. In conclusion, this study provided in vivo and in vitro mechanistic evidence for the antihyperuricemic, antioxidative and antiinflammatory effects of triphala for the first time, rationalizing its therapeutic usage for the treatment of hyperuricemia of gout.
Experimental

Biological materials and Extraction:
The fresh fruits of P. emblica, T. chebula, and T. belerica were collected from Doi saket district, Chiang Mai, Thailand in July, 2015. Plant materials were authenticated by Assist. Prof. Wanida Caichampoo, Mahasarakham University. The voucher specimens of P. emblica (MSU.PH-EUP-PE01), T. chebula (MSU.PH-COM-TC01), and T. belerica (MSU.PH-COM-TB01) were deposited at Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand. Seed of each fruit was removed, then seedless fruits were dried in hot air oven at 60ºC for 48 hr. The dried seedless fruits were blended using blender and sieved through mesh No. 14. Triphala was formulated by mixing 20 g each of P. emblica, T. chebula and T. belerica powders.
The mixture was then boiled with 1 L of distilled water for 1 h. The liquid part was filtered through a Whatman filter paper No. 1. The filtrate was collected and further treated to dryness by freeze drying technique. The obtained extract was kept in a closed container under light protection at -20 ºC until used for analysis.
Preparation of standard and sample solutions:
Stock solutions of standard gallic acid (1 mg/mL) and ellagic acid (1 mg/mL) in methanol were freshly prepared prior to use. Triphala was dissolved in 50% methanol, filtered through 0.45 µm PTFE syringe filter and the filtrates were used for HPLC analysis as described below.
Quantitative analysis of bioactive markers:
Ellagic acid and gallic acid were used as chemical markers of the triphala extract. Quantitative analysis of ellagic and gallic acids was performed using an HPLC system (Shimadzu SCL-10A VP, Kyoto, Japan). The analytical method used was modified from a previous study [8] . Animals: Male ddY mice (30-40 g) were purchased and housed in the animal center at Showa University, Tokyo, Japan at a constant temperature (25 ± 1C) with a 12 hours light-dark cycle and had free access to standard diet and water ad libitum. Mice were acclimatized for 7 days before starting the experiment. All procedures were approved by the animal ethics committee of Showa University with the permission number 27061.
Induction of hyperuricemia in mice:
Hyperuricemic mice were developed using potassium oxonate (300 mg/kg i.p.) .The mice were randomly divided into 6 groups (n=6) nominated as groups 1 to 6. Group 1 corresponds to normal control mice. Groups 2 to 6 correspond to potassium oxonate-induced hyperuricemic mice administered orally with water, allopurinol (5 mg/kg) and triphala at doses of 500 mg/kg, 1,000 mg/kg and 1,500 mg/kg, respectively. Each treatment was given consecutively for 7 days. On the 7 th day, after 1 h after the treatment, mice in groups 2 to 6 were orally administered with 300 mg/kg xanthine (i.e., xanthine oxidase substrate) dispersed in 0.5 %CMC-Na, while group 1 was orally administered with 0.5% CMC -Na. Then, 2 h after receiving the pretreatment, mice were euthanized with CO 2 inhalation, and blood was collected by cardiac heart puncture. Consecutively, mice livers 
